Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers

類似資料

• Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis
  著者:: Yasameen Abbas, 等
  出版事項: (2024-12-01)
• A prospective, randomized, double-blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate
  著者:: Prasad Apsangikar, 等
  出版事項: (2018-01-01)
• Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
  著者:: Т. V. Korotaeva, 等
  出版事項: (2018-12-01)
• Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason
  著者:: Giammarco Mocci, 等
  出版事項: (2023-10-01)
• Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases
  著者:: Ran Jin, 等
  出版事項: (2024-03-01)